Understanding the role of the cGAS-STING pathway and senescence in the ovarian aging

Understanding the Role of the Cgas-sting Pathway and Senescence in the Ovarian Aging

FACC

Reproductive longevity

The project aims to investigate the role of the cGAS-STING pathway and cellular senescence in ovarian aging, with a focus on developing treatments to prevent ovarian reserve loss during aging and improve ovarian reserve in patients DOR and those undergoing chemotherapy.

Owned by

0x4D754…cF42f

Contract:

0x3c426…2d9d3

Description

Team

0x4d754…cf42f

Owner

Organisation

Pablo de Olavide University

Experiment Cost

$120,200.00

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Price of FACC

$0.161

Project Progress

All updates

All categories

Timeline

Activity

Time	Type	$FACC	USD	ETH	From

Understanding the Role of the Cgas-sting Pathway and Senescence in the Ovarian Aging

FACC

Reproductive longevity

Owned by

0x4D754…cF42f

Contract:

0x3c426…2d9d3

Description

Team

0x4d754…cf42f

Owner

Organisation

Pablo de Olavide University

Experiment Cost

$120,200.00

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Price of FACC

$0.161

Project Progress

All updates

All categories

Timeline

Activity

Time	Type	$FACC	USD	ETH	From

Rationale

The project has conducted multiple in vivo efficacy studies in disease-relevant aged mouse models (9-month and 12-month-old female mice representing natural ovarian aging), demonstrating early proof-of-concept with measurable, clinically relevant outcomes including increased ovarian follicle counts, elevated AMH levels, and improved pregnancy rates compared to vehicle controls. These naturally aged mouse models recapitulate key pathophysiological features of human ovarian aging, and the results show quantifiable therapeutic effects across reproductive and metabolic endpoints, clearly meeting TRL 3 criteria for early-stage efficacy in disease-relevant preclinical models.

Assessment

High Confidence

RecommendationSUPPLEMENT

Total Score3.30

Overall Assessment

The AthenaDAO FACC IPT project scores a final weighted score of 3.30 out of 5.00, placing it in the moderate-to-good range for a TRL 3 project. The project's strongest attributes are its therapeutic relevance (score: 4) and utility of candidates (score: 4), reflecting solid in vivo proof-of-concept data with compound A2 demonstrating meaningful efficacy in reproductive aging endpoints (ovarian follicles, AMH, pregnancy rates) and early metabolic benefits. Therapeutic optionality is also strong (score: 4) given the broad applicability of STING inhibition across inflammatory conditions. The key areas requiring attention are: (1) Intellectual Property (score: 3) — the EPO filing is a good start but needs expansion to other jurisdictions and broader claim coverage; (2) Safety (score: 3) — encouraging preliminary signals but formal toxicology studies are critical and planned for next year; (3) Clinical Development (score: 2) and GMP/CMC (score: 2) — both are expectedly early at TRL 3 but represent significant work ahead before IND filing. The organizational infrastructure (score: 3) needs strengthening, particularly the CEO hire and addition of regulatory/CMC expertise. Overall, the project demonstrates strong scientific foundations with a validated mechanism and promising preclinical efficacy data, but faces typical TRL 3 challenges in translating these findings toward clinical development. The next 12-18 months — encompassing formal toxicology, PK characterization, IP expansion, and spinout maturation — will be critical in determining whether the project can advance to TRL 4.

Weighted Score

Therapeutic Relevance

The STING pathway is a well-validated inflammatory signaling axis with clear therapeutic relevance to ovarian aging and systemic inflammation. The mechanism is supported by strong experimental validation: A2 demonstrated excellent STING inhibition in an in vivo systemic inflammation model, and the 1-month oral study in middle-aged mice showed meaningful improvements in ovarian follicles, AMH levels, and pregnancy rates. The ongoing 3-month study in older mice further supports relevance with early metabolic benefit signals (glucose tolerance, welfare). However, the link between STING inhibition and ovarian aging specifically, while biologically plausible, is still an emerging area without extensive clinical validation, preventing a score of 5.

Therapeutic Optionality

There are clear indications of expandability beyond the primary ovarian aging indication. The 3-month study already shows early signals of metabolic benefit (improved glucose tolerance), suggesting potential in metabolic disease. STING inhibition has broad relevance across inflammatory and autoimmune conditions. Additionally, negotiations with Pablo Olavide University to add another inflammation-related asset further demonstrate pipeline optionality. The mechanism inherently supports multiple disease areas (neuroinflammation, metabolic syndrome, fibrosis, etc.), though these have not yet been experimentally explored with A2 specifically.

Intellectual Property

A composition of matter patent for A2 and related compounds is being filed at the European Patent Office, which is a positive step providing potential chemical matter exclusivity. However, the IP strategy appears to be in early stages — filing is in progress (not granted), and there is no mention of filings in other major jurisdictions (USPTO, JPO, etc.), freedom-to-operate analyses, or a broader IP strategy covering methods of use, formulations, or combination claims. The STING inhibitor space is competitive with several players (e.g., GSK, Novartis), which could present FTO challenges. The score reflects an IP strategy that is initiated but not yet robust or comprehensive.

Utility Of Candidates

Compound A2 demonstrates strong early efficacy in relevant disease models. The completed 1-month oral study in middle-aged mice showed increases in ovarian follicles, AMH, and pregnancy rates — all clinically meaningful reproductive endpoints. The ongoing 3-month study in older mice shows early signals of improved glucose tolerance and welfare. The compound is orally bioavailable (oral dosing route used successfully), which is a significant advantage for a chronic indication. PK profiling has been initiated at WuXi AppTec, indicating the compound is progressing through lead characterization. However, dose-response data, target engagement biomarkers, and detailed pharmacodynamic characterization are not mentioned, and only one lead compound is discussed without backup candidates, which slightly limits the score.

Prospects For Safety

The safety profile is encouraging but preliminary. Long-term studies conducted to date show no toxicity for A2, and offspring from treated dams show no adverse developmental effects — both are positive signals. However, formal dedicated toxicology studies have not yet been initiated (planned for next year), meaning there is no systematic safety assessment including histopathology, hematology, organ function panels, or dose-limiting toxicity determination. STING pathway inhibition carries theoretical immunosuppression risks that need formal evaluation. The current safety data is observational rather than from structured GLP-compliant toxicology studies, so while reassuring, it is insufficient for a higher score.

Prospects For Gmp Cmc

There is very limited information on GMP/CMC readiness. The compound is being synthesized and used in animal studies, and PK profiling has been sent to WuXi AppTec, but there is no mention of synthetic route optimization, scalability assessment, formulation development, stability studies, or GMP manufacturing planning. At TRL 3 this is somewhat expected, but the absence of any CMC-related discussion or planning suggests this area has not yet been addressed. Manufacturing challenges for A2 are unknown from the available data.

Prospects For Clinical Development

Clinical development is still distant. PK profiling has just been initiated, formal toxicology is planned for next year, and there is no mention of IND-enabling study planning, clinical trial design, regulatory pre-IND interactions, patient population definition, or clinical endpoint selection. The project is appropriately focused on preclinical work at this stage, but the path to clinical trials has not been articulated. The spinout is still forming (CEO search active), which means the organizational infrastructure for clinical development is not yet in place. Regulatory strategy and clinical development planning appear to be future activities.

Commercial Potential

The commercial potential is moderate to promising. Ovarian aging and female reproductive longevity represent a growing market with significant unmet need and no approved pharmacological interventions specifically targeting ovarian reserve preservation. The broader inflammation and metabolic indications expand the addressable market. However, the STING inhibitor space is becoming competitive, and the project is very early-stage with no clear commercialization timeline. The spinout is still in formation with an active CEO search, and commercial strategy has not been articulated. The niche focus on ovarian aging could be both an advantage (first-mover) and a limitation (smaller initial market).

Organization And Team Fit

The team has demonstrated scientific expertise through Mario's lab, which identified and validated the compound through multiple in vivo studies. AthenaDAO provides a supporting framework, and the spinout formation indicates intent to build a proper organizational structure. However, there are notable gaps: the spinout lacks a CEO (active search), and there is no mention of regulatory, CMC, or clinical development expertise on the team. The reliance on CROs (WuXi AppTec) for key activities is appropriate at this stage but highlights internal capability limitations. The negotiation with Pablo Olavide University for additional assets suggests academic collaboration strength but also potential complexity in IP and governance.